Canada Markets closed

Graybug Vision, Inc. (GRAY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.3200-0.0500 (-3.65%)
At close: 04:00PM EST
1.3800 +0.06 (+4.55%)
After hours: 04:22PM EST

Graybug Vision, Inc.

275 Shoreline Drive
Suite 450
Redwood City, CA 94065
United States
650 487 2800

Full Time Employees24

Key Executives

NameTitlePayExercisedYear Born
Dr. Frederic Guerard Pharm.D.Pres, CEO & Director873.62kN/A1972
Mr. Robert S. BreuilChief Financial Officer441.08kN/A1962
Dr. Gerald D. Cagle Ph.D.Sr. Advisor, Head of Bus. Devel. & Director11.17kN/A1944
Dr. Parisa Zamiri M.D., Ph.D.Chief Medical Officer468.51kN/A1965
Dr. Peter A. Campochiaro M.D.Co-FounderN/AN/AN/A
Dr. Peter J. McDonnellCo-FounderN/AN/A1959
Ms. Bettina MaunzChief People Officer & Head of CommunicationsN/AN/AN/A
Mr. Ming YangSr. VP of R&DN/AN/AN/A
Dr. Ward M. Peterson Ph.D.Sr. VP of Preclinical Devel.N/AN/AN/A
Mr. Ali KakavandVP & Head of Program ManagementN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

Corporate Governance

Graybug Vision, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.